Message from the Guest Editor

Dear Colleagues,

Proton therapy was introduced in the 1940s and carbon-ion therapy was started in the 1990s. Recently the particle therapy of protons and carbon ions has spread to many countries around the world. Compared to conventional radiation treatment with X-rays, there are clinical reports that particle therapy is more effective against: 1) malignant tumors with less X-ray sensitivity; 2) tumors close to vital organs; and 3) large tumors.

In this Special Issue, we would like to discuss how particle therapy is employed for cancers that are difficult to treat with X-ray therapy, as well as possible future uses of this therapy and its current state of progress. It would also be beneficial to look into the efficacy of combining particle therapy with chemotherapy.

If we are able to clarify the strong points of ion beam radiotherapy in this special edition, we can expect progress on differentiating the uses of proton therapy and carbon-ion therapy from X-ray radiotherapy.

We also welcome advice from facilities that have experience with proton therapy and/or carbon-ion therapy to those medical institutions that are considering introducing it.
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI